282 related articles for article (PubMed ID: 24397165)
41. [Prospective pioglitazone clinical trial in macrovascular events].
Asanuma H; Kitakaze M
Nihon Rinsho; 2012 May; 70 Suppl 3():301-8. PubMed ID: 22768537
[No Abstract] [Full Text] [Related]
42. Cardiovascular risk and cardiometabolic protection: role of glitazones.
Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
[TBL] [Abstract][Full Text] [Related]
43. Choice of antihypertensive drug in the diabetic patient.
Ong HT; Cheah JS
MedGenMed; 2005 May; 7(2):74. PubMed ID: 16369452
[TBL] [Abstract][Full Text] [Related]
44. Implications of stroke prevention trials: treatment of global risk.
Elkind MS
Neurology; 2005 Jul; 65(1):17-21. PubMed ID: 16009880
[TBL] [Abstract][Full Text] [Related]
45. Hypoglycemia as a driver of cardiovascular risk in diabetes.
Moheet A; Seaquist ER
Curr Atheroscler Rep; 2013 Sep; 15(9):351. PubMed ID: 23881546
[TBL] [Abstract][Full Text] [Related]
46. [Improvement in cardiovascular prognosis of type 2 diabetes mellitus, is it a reality?].
Ruiz-Hurtado G; Vigil L; Ruilope LM
Hipertens Riesgo Vasc; 2016; 33(4):123-125. PubMed ID: 27770841
[No Abstract] [Full Text] [Related]
47. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II.
Beckman JA; Paneni F; Cosentino F; Creager MA
Eur Heart J; 2013 Aug; 34(31):2444-52. PubMed ID: 23625211
[TBL] [Abstract][Full Text] [Related]
48. Pharmacological strategies to reduce cardiovascular risk in type 2 diabetes mellitus: an update.
Hovens MM; Tamsma JT; Beishuizen ED; Huisman MV
Drugs; 2005; 65(4):433-45. PubMed ID: 15733008
[TBL] [Abstract][Full Text] [Related]
49. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease.
Fonseca VA
Am J Cardiol; 2003 Aug; 92(4A):50J-60J. PubMed ID: 12957327
[TBL] [Abstract][Full Text] [Related]
50. Vascular disease and lipids in diabetes.
Garber AJ
Med Clin North Am; 1998 Jul; 82(4):931-48. PubMed ID: 9706127
[TBL] [Abstract][Full Text] [Related]
51. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome.
Bestermann W; Houston MC; Basile J; Egan B; Ferrario CM; Lackland D; Hawkins RG; Reed J; Rogers P; Wise D; Moore MA
Am J Med Sci; 2005 Jun; 329(6):292-305. PubMed ID: 15958871
[TBL] [Abstract][Full Text] [Related]
52. Blood pressure control in type 2 diabetes.
de Galan BE
N Engl J Med; 2010 Aug; 363(7):695-6; author reply 697. PubMed ID: 20842774
[No Abstract] [Full Text] [Related]
53. [Prevention of cardiovascular diseases using a combined pharmacological approach: is there any place for a "polypill"?].
Scheen AJ; Lefèbvre PJ; Kulbertus H
Rev Med Liege; 2003 Sep; 58(9):527-33. PubMed ID: 14626644
[TBL] [Abstract][Full Text] [Related]
54. Vascular disease in paediatric type 2 diabetes: the state of the art.
Vaughan TB; Ovalle F; Moreland E
Diab Vasc Dis Res; 2007 Dec; 4(4):297-304. PubMed ID: 18158699
[TBL] [Abstract][Full Text] [Related]
55. Systemic antiatherosclerotic treatment for the peripheral arterial occlusive disease patient.
Baumgartner I
Expert Opin Pharmacother; 2005 Oct; 6(13):2181-92. PubMed ID: 16218880
[TBL] [Abstract][Full Text] [Related]
56. Drugs for type 2 diabetes mellitus: the imperative for cardiovascular outcome assessment.
Gore MO; McGuire DK
Diab Vasc Dis Res; 2012 Apr; 9(2):85-8. PubMed ID: 22496441
[No Abstract] [Full Text] [Related]
57. Combination therapy to prevent cardiovascular disease: slow progress.
Smith R; McCready T; Yusuf S
JAMA; 2013 Apr; 309(15):1595-6. PubMed ID: 23529576
[No Abstract] [Full Text] [Related]
58. Polypill: Can its Potential Enhancement of Efficacy Trigger New Interest?
Chao J; Bansilal S
Glob Heart; 2016 Dec; 11(4):469-472. PubMed ID: 27938845
[No Abstract] [Full Text] [Related]
59. Improving cardiovascular protection: focus on a cardiovascular polypill.
Barrios V; Escobar C
Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213
[TBL] [Abstract][Full Text] [Related]
60. [Cardiovascular safety of antidiabetics].
Aline Roth PW; Jornayvaz FR
Rev Med Suisse; 2016 Jun; 12(521):1084, 1086-8. PubMed ID: 27487675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
